Vestergaard L, Andersen K E
Odense Universitetshospital, dermato-venerologisk afdeling I.
Ugeskr Laeger. 1997 Sep 15;159(38):5662-6.
We studied the frequency of contact dermatitis to corticosteroids in consecutive eczema patients and the relevance of positive patch test reactions. Of 2,742 patients patch tested at the Dermatology Clinic at Odense University Hospital between June 1991 and December 1995, 65 patients (47 women and 18 men) or 2.4% had a positive reaction to one or more of the corticosteroids tested. Forty (1.45%) had a positive reaction to budesonide 1% pet. in the standard series. For a one-year period 662 consecutive eczema patients were routinely patch tested with a corticosteroid series consisting of five steroid allergens, and 17 had a positive reaction to at least one of these (2.6%). Budesonide allergy was most often encountered, followed by hydrocortisone, tixocortol pivalate and hydrocortisone-17-butyrate. Betamethasone valerate, triamcinolone acetonide and clobetasol propionate rarely caused contact allergy. The corticosteroid allergy was of current relevance in about one third of the cases. Corticosteroid contact allergy is an uncommon adverse effect, in relation to the number of patients with inflammatory skin diseases who are treated with topical corticosteroids. In patients with longstanding eczematous skin disease, who do not improve or deteriorate during topical corticosteroid therapy, contact allergy to these drugs should be suspected and relevant patch tests should be performed to sort out concomitant reactions. Future treatment with corticosteroids must take into account possible cross-reactions.
我们研究了连续性湿疹患者中接触性皮炎对皮质类固醇的发生率以及斑贴试验阳性反应的相关性。在1991年6月至1995年12月期间于欧登塞大学医院皮肤科诊所接受斑贴试验的2742例患者中,65例患者(47例女性和18例男性),即2.4%,对一种或多种受试皮质类固醇有阳性反应。40例(1.45%)对标准系列中1%的布地奈德凡士林制剂有阳性反应。在为期一年的时间里,662例连续性湿疹患者常规接受了由五种类固醇变应原组成的皮质类固醇系列斑贴试验,其中17例对其中至少一种有阳性反应(2.6%)。布地奈德过敏最为常见,其次是氢化可的松、匹伐酸替可的松和丁酸氢化可的松。戊酸倍他米松、曲安奈德和丙酸氯倍他索很少引起接触性过敏。约三分之一的病例中,皮质类固醇过敏具有当前相关性。相对于接受外用皮质类固醇治疗的炎症性皮肤病患者数量而言,皮质类固醇接触过敏是一种不常见的不良反应。在长期患有湿疹性皮肤病且在局部皮质类固醇治疗期间病情无改善或恶化的患者中,应怀疑对这些药物的接触过敏,并应进行相关斑贴试验以区分伴随反应。未来使用皮质类固醇进行治疗时必须考虑可能的交叉反应。